{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:03:51Z","timestamp":1789423431036,"version":"build-2803163510"},"reference-count":85,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.mcna.2022.12.008","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T12:29:44Z","timestamp":1676896184000},"page":"623-640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors"],"prefix":"10.1016","volume":"107","author":[{"given":"Fernando","family":"Bessone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar S.","family":"Bj\u00f6rnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2022.12.008_bib1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hep.28323","article-title":"Categorization of drugs implicated in causing liver injury: critical assessment based upon published case reports","volume":"63","author":"Bj\u00f6rnsson","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.mcna.2022.12.008_bib3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1056\/NEJMra1816149","article-title":"Drug induced liver injury: types and phenotypes","volume":"381","author":"Hoofnagle","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2022.12.008_bib4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/hep4.1465","article-title":"Biologic and checkpoint inhibitor-induced liver injury: a systematic literature review","volume":"4","author":"Shah","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.mcna.2022.12.008_bib5","doi-asserted-by":"crossref","first-page":"486","DOI":"10.14218\/JCTH.2021.00243","article-title":"Hepatotoxicity induced by biological agents: clinical features and current controversies","volume":"10","author":"Hernandez","year":"2022","journal-title":"J\u00a0Clin Transpational Hepatol"},{"key":"10.1016\/j.mcna.2022.12.008_bib6","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41397-020-0159-0","article-title":"HLA Associations with Infliximab-Induced Liver Injury","volume":"5","author":"Bruno","year":"2020","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"10.1016\/j.mcna.2022.12.008_bib7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jhep.2021.08.024","article-title":"Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment","volume":"76","author":"Bj\u00f6rnsson","year":"2022","journal-title":"J\u00a0Hepatol J Hepatol"},{"key":"10.1016\/j.mcna.2022.12.008_bib8","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.cgh.2014.07.062","article-title":"The risk of drug-induced liver injury from Tumor Necrosis Factor (TNF)-alpha-antagonists","volume":"13","author":"Bj\u00f6rnsson","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.mcna.2022.12.008_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.02.017","article-title":"Can azathioprine prevent infliximab-induced liver injury?","author":"Meunier","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.mcna.2022.12.008_bib10","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/apt.13994","article-title":"Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease","volume":"45","author":"Strik","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.mcna.2022.12.008_bib11","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, Presentation and Outcomes in Patients with Drug-Induced Liver Injury in the General Population of Iceland","volume":"144","author":"Bjornsson","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mcna.2022.12.008_bib12","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/apt.13159","article-title":"New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease","volume":"41","author":"Shelton","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.mcna.2022.12.008_bib13","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.3748\/wjg.v23.i22.4102","article-title":"Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study","volume":"23","author":"Koller","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.mcna.2022.12.008_bib14","first-page":"162","article-title":"Retrospective study of idiosyncratic drug-induced liver injury from infliximab in an inflammatory bowel disease cohort: the IDLE study","volume":"33","author":"Worland","year":"2020","journal-title":"Ann Gastroenterol"},{"issue":"5","key":"10.1016\/j.mcna.2022.12.008_bib15","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2012.12.025","article-title":"Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases","volume":"11","author":"Ghabril","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.mcna.2022.12.008_bib16","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.3748\/wjg.v21.i24.7584","article-title":"Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases","volume":"21","author":"Rodrigues","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.mcna.2022.12.008_bib17","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/hep4.1959","volume":"6","author":"Bj\u00f6rnsson","year":"2022","journal-title":"Setting Up Criteria Hepatol Commun"},{"key":"10.1016\/j.mcna.2022.12.008_bib18","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s10067-008-0885-1","article-title":"A\u00a0case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis","volume":"27","author":"Harada","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.mcna.2022.12.008_bib19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/RHU.0b013e318188b1df","article-title":"Development of autoimmune hepatitis in a child with systemic-onset juvenile idiopathic arthritis during therapy with etanercept","volume":"14","author":"Fathalla","year":"2008","journal-title":"J\u00a0Clin Rheumat"},{"key":"10.1016\/j.mcna.2022.12.008_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cgh.2010.07.016","article-title":"Patients with typical laboratory features of Autoimmune Hepatitis rarely need a liver biopsy for diagnosis","volume":"9","author":"Bjornsson","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.mcna.2022.12.008_bib21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2165\/00044011-200626110-00008","article-title":"Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis","volume":"26","author":"Lerhardi","year":"2006","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.mcna.2022.12.008_bib22","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4065\/76.1.84","article-title":"Infliximab-associated reversible cholestatic liver disease","volume":"76","author":"Menghini","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.mcna.2022.12.008_bib23","first-page":"1624","article-title":"Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still\u2019s disease","volume":"30","author":"Michel","year":"2003","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.mcna.2022.12.008_bib24","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/ard.62.7.686","article-title":"Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate","volume":"62","author":"Ostuni","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mcna.2022.12.008_bib25","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2004.040675","article-title":"Chronic hepatitis B reactivation following infliximab therapy in Crohn\u2019s disease patients: need for primary prophylaxis","volume":"53","author":"Esteve","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.mcna.2022.12.008_bib26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunsuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mcna.2022.12.008_bib27","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10067-005-0169-y","article-title":"Serious liver disease induced by infliximab","volume":"26","author":"Tobon","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.mcna.2022.12.008_bib28","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.crohns.2012.02.004","article-title":"A\u00a0case report: ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis","volume":"6","author":"Kinnunen","year":"2012","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.mcna.2022.12.008_bib29","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.gcb.2010.01.016","article-title":"Infliximab induced acute hepatitis during Crohn\u2019s disease therapy: absence of cross-toxicity with adalimumab","volume":"34","author":"Haennig","year":"2010","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.mcna.2022.12.008_bib30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.annder.2012.10.601","article-title":"Infliximab-induced hepatitis during treatment of vulvar Crohn\u2019s disease [in French]","volume":"140","author":"Causs\u00e9","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.mcna.2022.12.008_bib31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s13256-015-0730-5","article-title":"Infliximab-associated fulminant hepatic failure in ulcerative colitis: a case report","volume":"9","author":"Parra","year":"2015","journal-title":"J\u00a0Med Case Rep"},{"key":"10.1016\/j.mcna.2022.12.008_bib32","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s00108-017-0205-4","article-title":"A\u00a020-year-old woman with ulcerative colitis and acute liver failure","volume":"58","author":"Forker","year":"2017","journal-title":"Internist (Berl)"},{"key":"10.1016\/j.mcna.2022.12.008_bib33","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1007\/s10620-018-5023-6","article-title":"United States Acute Liver Failure Study Group. Acute liver failure from tumor necrosis factor-a antagonists: report of four cases and literature review","volume":"63","author":"Kok","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.mcna.2022.12.008_bib34","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/ccr3.2456","article-title":"Infliximab-induced autoim- mune hepatitis requiring liver transplanEiswerthtation","volume":"7","author":"Wong","year":"2019","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.mcna.2022.12.008_bib35","doi-asserted-by":"crossref","first-page":"e00586","DOI":"10.14309\/crj.0000000000000586","article-title":"Infliximab-induced acute liver failure in a patient with crohn's disease requiring orthotopic liver transplantation","volume":"8","author":"Mustafa Alikhan","year":"2021","journal-title":"ACG Case Rep J"},{"key":"10.1016\/j.mcna.2022.12.008_bib36","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/hep.28967","article-title":"Clinical presentation and outcomes of bile duct loss caused by drugs and dietary supplements","volume":"65","author":"Bonkovsky","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.mcna.2022.12.008_bib37","doi-asserted-by":"crossref","first-page":"e00134","DOI":"10.14309\/crj.0000000000000134","article-title":"Now You See It, Now You Don\u2019t: a case report of Infliximab-induced vanishing bile duct syndrome","volume":"6","author":"Shah","year":"2019","journal-title":"ACG Case Rep"},{"key":"10.1016\/j.mcna.2022.12.008_bib38","first-page":"e21940","article-title":"Infliximab-induced vanishing bile duct syndrome","volume":"14","author":"Eiswerth","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.mcna.2022.12.008_bib39","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1634\/theoncologist.2014-0422","article-title":"The evolving role of immune checkpoint inhibitors in cancer treatment","volume":"20","author":"Pennock","year":"2015","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.mcna.2022.12.008_bib40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/biomedicines9020101","article-title":"Checkpoint inhibitors and hepatotoxicity","volume":"9","author":"Malnick","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.mcna.2022.12.008_bib41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.mcna.2022.12.008_bib42","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2022.12.008_bib43","unstructured":"Opdualag prescribing information. Opdualag U.S. Product information, 2022, Bristol-Myers Squibb Company; Princeton, NJ, Available at: https:\/\/news.bms.com\/news\/details\/2022\/U.S.-Food-and-Drug-Administration-Approves-First-LAG-3-Blocking-Antibody-Combination-Opdualag-nivolumab-and-relatlimab-rmbw-as-Treatment-for-Patients-with-Unresectable-or-Metastatic-Melanoma\/default.aspx. Accessed September 16, 2022."},{"issue":"2","key":"10.1016\/j.mcna.2022.12.008_bib44","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","article-title":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"72","author":"Sangro","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.mcna.2022.12.008_bib45","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s12325-019-01034-0","article-title":"Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab","volume":"36","author":"Lanitis","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.mcna.2022.12.008_bib46","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-Related Adverse Events Associated with Anti-PD-1\/PD-L1 Treatment for Malignancies: A Meta-Analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.mcna.2022.12.008_bib47","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.mcna.2022.12.008_bib48","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10\u00a0mg\/kg versus ipilimumab 3\u00a0mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.mcna.2022.12.008_bib49","doi-asserted-by":"crossref","first-page":"e0157111","DOI":"10.1371\/journal.pone.0157111","article-title":"Understanding and Controlling Sialylation in a CHO Fc-Fusion Process","volume":"11","author":"Croughan","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.mcna.2022.12.008_bib50","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"32","key":"10.1016\/j.mcna.2022.12.008_bib51","first-page":"5376","article-title":"Immune checkpoint inhibitor-related hepatotoxicity: A review World","volume":"27","author":"Remash","year":"2021","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.mcna.2022.12.008_bib52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1189\/jlb.1212621","article-title":"At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy","volume":"94","author":"Intlekofer","year":"2013","journal-title":"J\u00a0Leukoc Biol"},{"issue":"12","key":"10.1016\/j.mcna.2022.12.008_bib53","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1007\/s00262-022-03203-7","article-title":"Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials Cancer","volume":"71","author":"Fujiwara","year":"2022","journal-title":"Immunol Immunother"},{"key":"10.1016\/j.mcna.2022.12.008_bib54","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/ijc.30678","article-title":"Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data","volume":"141","author":"Wang","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.mcna.2022.12.008_bib55","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2022.12.008_bib56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double- Blind, Phase III Trial","volume":"38","author":"Finn","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.mcna.2022.12.008_bib57","article-title":"Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival","author":"Miah","year":"2022","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"10","key":"10.1016\/j.mcna.2022.12.008_bib58","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/14740338.2022.2134854","article-title":"Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"21","author":"Pana","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.mcna.2022.12.008_bib59","first-page":"1","article-title":"A\u00a0new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry","volume":"00","author":"Bj\u00f6rnsson","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.mcna.2022.12.008_bib60","unstructured":"FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma, Available at: www.fda.gov\/drugs\/drug-approvals-anddatabases\/fda-approves-atezolizumab-plus-bevacizumab-unresectablehepatocellular-carcinoma. Accessed June 1, 2020."},{"key":"10.1016\/j.mcna.2022.12.008_bib61","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.mcna.2022.12.008_bib62","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.4254\/wjh.v14.i7.1269","article-title":"Checkpoint inhibitor-induced hepatotoxicity: role of liver biopsy and management approach","volume":"14","author":"Bessone","year":"2022","journal-title":"World J Hepatol"},{"key":"10.1016\/j.mcna.2022.12.008_bib63","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.mcna.2022.12.008_bib64","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.mcna.2022.12.008_bib65","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/COC.0000000000000374","article-title":"Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management","volume":"41","author":"Huffman","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1016\/j.mcna.2022.12.008_bib66","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00535-020-01677-9","article-title":"Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies","volume":"55","author":"Kazuyuki","year":"2020","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.mcna.2022.12.008_bib67","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/jgh.14136","article-title":"Hepatobiliary AND PANCREATIC: NIVOLUMAB-RELATED CHolangiopathy","volume":"33","author":"Hamoir","year":"2018","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.mcna.2022.12.008_bib68","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.dld.2015.03.002","article-title":"Secondary sclerosing cholangitis in patients with drug-induced liver injury","volume":"47","author":"Gudnason","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.mcna.2022.12.008_bib69","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.cgh.2018.06.035","article-title":"Sclerosing cholangitis-like changes on magnetic resonance cholangiography in patients with drug induced liver injury","volume":"17","author":"Ahmad","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.mcna.2022.12.008_bib70","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41379-020-00653-1","article-title":"Liver biopsy findings in patients on immune checkpoint inhibitors","volume":"34","author":"Cohen","year":"2021","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.mcna.2022.12.008_bib71","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","article-title":"Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review","volume":"26","author":"Onoyama","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.mcna.2022.12.008_bib72","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jamaoncol.2021.4342","article-title":"Utility of Liver Biopsy in Diagnosis and Management of High-grade Immune Checkpoint Inhibitor Hepatitis in Patients With Cancer","volume":"7","author":"Li","year":"2021","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.mcna.2022.12.008_bib73","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl 4","key":"10.1016\/j.mcna.2022.12.008_bib74","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.mcna.2022.12.008_bib75","unstructured":"Management of immune-related adverse events (irAEs) | eviQ, Available at: https:\/\/www.eviq.org.au\/clinical-resources\/side-effect-and-toxicitymanagement\/immunological\/1993-management-of-immune-relatedadverse-events#collapse150419. Accessed March 4, 2022."},{"issue":"17","key":"10.1016\/j.mcna.2022.12.008_bib76","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.mcna.2022.12.008_bib77","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.mcna.2022.12.008_bib78","doi-asserted-by":"crossref","first-page":"251","DOI":"10.14309\/ajg.0000000000000398","article-title":"Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors","volume":"115","author":"Miller","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mcna.2022.12.008_bib79","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/COC.0000000000000374","article-title":"Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management","volume":"41","author":"Huffman","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.mcna.2022.12.008_bib80","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jhep.2018.03.034","article-title":"Immune-related hepatitis with immunotherapy: are corticosteroids always needed?","volume":"69","author":"Gauci","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.mcna.2022.12.008_bib81","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/liv.14489","article-title":"Immune-related hepatitis related to checkpoint inhibitors: clinical and prognostic factors","volume":"40","author":"Riveiro-Barciela","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.mcna.2022.12.008_bib82","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jhep.2018.06.012","article-title":"Mortality due to immunotherapy related hepatitis","volume":"69","author":"Bhave","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.mcna.2022.12.008_bib83","article-title":"AASLD practice guidance on drug, herbal, and dietary supplement\u2013induced liver injury","author":"Fontana","year":"2022","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.mcna.2022.12.008_bib84","first-page":"1222","article-title":"European Association for the Study of the Liver; Clinical Practice Guideline Panel: Chair; Panel members; EASL Governing Board representative. EASL Clinical Practice Guidelines: Drug-induced liver injury","volume":"70","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.mcna.2022.12.008_bib85","first-page":"e1624","article-title":"Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review","volume":"5","author":"Ueno","year":"2022","journal-title":"Cancer Rep"},{"issue":"4","key":"10.1016\/j.mcna.2022.12.008_bib86","doi-asserted-by":"crossref","first-page":"e000268","DOI":"10.1136\/esmoopen-2017-000268","article-title":"Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury","volume":"2","author":"Doherty","year":"2017","journal-title":"ESMO Open"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002571252200178X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002571252200178X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:48:10Z","timestamp":1758419290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002571252200178X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S002571252200178X"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2022.12.008","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2022.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}